USFDA adds strict safety warnings on Pfizer, AbbVie, Lilly arthritis drugs

New Delhi: The U.S. health regulator has added its strictest warning to the labels of drugs from Pfizer, Eli Lilly and AbbVie belonging to a class of anti-inflammatory treatments called JAK inhibitors, citing risk of serious health issues and death in patients 50 and over, the drugmakers said on Friday.The addition of the warning on the labels follows the agency's review of Pfizer's Xeljanz...
New Delhi: The U.S. health regulator has added its strictest warning to the labels of drugs from Pfizer, Eli Lilly and AbbVie belonging to a class of anti-inflammatory treatments called JAK inhibitors, citing risk of serious health issues and death in patients 50 and over, the drugmakers said on Friday.
Read also: Johnson & Johnson COVID-19 vaccine may lead to Guillain-Barre syndrome, FDA to issue warning